- Chardan Research initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA) with a Buy rating and a price target of $29 and Dyne Therapeutics Inc (NASDAQ:DYN) with a Buy rating and a price target of $17.
- “We believe that Avidity and Dyne are an intriguing small-cap story that, while not immune to the selloff of the biotech sector over the past seven months, warrants a fresh look by investors, Chardan analysts wrote.
- Chardan says Avidity’s antibody oligonucleotide conjugate (AOC) design and Dyne’s proprietary FORCE design platform leverage well-characterized components.
- Related: Avidity Biosciences Or Dyne Therapeutics – Read On Raymond James’ Rating Skew.
- “The value created by the companies thus far is the well-characterized understanding of how to get all of the components to work together in an optimum fashion,” Chardan added.
- Hence, the key reason Chardan believes that Avidity’s AOC and Dyne’s FORCE design approach is an enabling technology that can advance small RNA therapeutics to move beyond the liver successfully.
- Price Action: DYN stock is down 0.93% at $10.35, and RNA shares are up 5.63% at $18.76 during the market session on the last check Wednesday.
Warrantee Inc. Announces Receipt Of Nasdaq Delisting Determination And Plan To Appeal; Co Plans To Appeal To The Panel In Due Course. A Hearing Request Will Stay The Suspension Of The Co’s Securities Pending The Panel’s Decision
Warrantee Inc. (NASDAQ:WRNT) (the "Company" or "Warrantee"), a Japanese marketing and market research technology company, today announced that the Company received a staff determination letter (the "Letter"), on April
